Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03054389 · ClinicalTrials.gov registry record
Non-Interventional Study to Capture the Patient Experience on Gene Therapy for Hemophilia Within the AskBio009-101 Study Through Patient and Investigator Interviews
A clinical trial, sponsored by Baxalta now part of Shire.
- Completed
- Registry status
- 27
- Enrollment target
NCT03054389: Completed study, sponsored by Baxalta now part of Shire.
NCT03054389 is a clinical trial that has completed, run by Baxalta now part of Shire. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03054389 has completed, sponsored by Baxalta now part of Shire.
- COMPLETED
- Registry status
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to seek to understand the patient's perspective around deciding to participate in a clinical trial for a Hemophilia therapy
Primary Outcome
Qualitative telephone interviews to understand the patient experience with the AskBio009-101 Study - Participant/ Patient Interview
Interventions
- OTHER Qualitative Interview - Participants/ Patients
- OTHER Qualitative Interview - Investigators and Study Coordinators
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2017-03-31 |
| Est. Completion | 2017-06-06 |
What the finished NCT03054389 record still lists
NCT03054389 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 27 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Qualitative Interview - Participants/ Patients is the first listed.
NCT03054389 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03054389 about?
NCT03054389 is a clinical study titled "Non-Interventional Study to Capture the Patient Experience on Gene Therapy for Hemophilia Within the AskBio009-101 Study Through Patient and Investigator Interviews". The purpose of this study is to seek to understand the patient's perspective around deciding to participate in a clinical trial for a Hemophilia therapy
What is the current status of trial NCT03054389?
This trial is currently completed. The enrollment target is 27 participants. The study started on 2017-03-31. Estimated completion is 2017-06-06.
What interventions are being tested in trial NCT03054389?
The interventions under investigation include: Qualitative Interview - Participants/ Patients (OTHER), Qualitative Interview - Investigators and Study Coordinators (OTHER).
Who is sponsoring clinical trial NCT03054389?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI